Omaha, NE (PRWEB) February 23, 2009
Omaha, Nebraska -- JN's Stroke vaccine could offer a "new dimension" in stroke prevention. The vaccine would most likely be targeted to people who are susceptible to strokes. Epilepsy, stroke, Parkinson's disease, Huntington, chronic pain, depression -- all might one day be treated and/or prevented with a new vaccine said Dr. Jeeri R. Reddy, the President and Scientific Director of the corporation.
Impact of Stroke:
Strokes occur in one of two ways; a blood clot forms and then cuts off circulation to part of the brain or a blood vessel ruptures and leaks blood into the brain. In both cases, a stroke can lead to permanent disability or death.
Stroke is the third leading killer in the United States, resulting in the following statistics annually: •750,000+ victims;
•160,000 deaths (3rd leading cause of death);
•266,000 survivors with permanent disabilities;
•30,000 new permanent admissions to nursing homes;
•Over 4 million living survivors of stroke;
•Every 45 seconds in the USA, someone has a stroke;
•Huge economic impact with costs of $40-$70 billion per year.
"Vaccines have always been an integral part of JN's business and our contribution to public health and saving lives and the startup of this new facility in Omaha intends to provide quality vaccines that prevent diseases and enhance health care for millions around the world. Vaccination prevents millions of deaths per year, and yet millions more are dying due to the lack of vaccines. Stringent regulatory hurdles and the perception of moderate returns on investment have not encouraged companies like us to enter the markets faster. Prevention is better than cure --innovation of new vaccines for healthcare make a real difference for the world. To realize this goal, we recognize that JN resources and capabilities are necessary, but not sufficient--we just can't do it alone. Successful, productive partnerships are essential for JN's ongoing pursuit of innovation and excellence," said Dr. Reddy.
JN-International Medical Corporation:
JN-International Medical Corporation is a U.S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. An Inc 5000 corporation, making it the 95th ranking company in the United States and the 3rd biopharmaceutical global corporation, it produces Meningitis vaccine for which it holds the international intellectual property rights (IPR).
JN boasts a decade of achievements including prevention of mother-to-child transmission of HIV in South East Asia, development of inexpensive vaccine for Meningococcal meningitis serogroups A, C, Y&W-135 and lately the discovery of a new generation preventive and therapeutic vaccine for Stroke and neurological disorders. The R&D division of JN-International is currently researching and developing vaccines for the prevention and cure of Hepatitis C, Herpes, Tuberculosis and a preventive and therapeutic vaccine for major Neurological disorders. JN-International Medical Corporation (JNI), based in Omaha, Nebraska, USA.
For more information:
Peter Grotzinger, director of public relations
JN-International Medical Corporation